In 2010, the FDA mandated that 4 companies marketing long-acting β2 agonists perform trials comparing the safety of combination therapy with LABA plus an inhaled glucocorticoid vs an inhaled glucocorticoid...
In 2010, the FDA mandated that 4 companies marketing long-acting β2 agonists perform trials comparing the safety of combination therapy with LABA plus an inhaled glucocorticoid vs an inhaled glucocorticoid...
In 2010, the FDA mandated that 4 companies marketing long-acting β2 agonists perform trials comparing the safety of combination therapy with LABA plus an inhaled glucocorticoid vs an inhaled glucocorticoid...
Based on the results of 3 placebo-controlled studies, the FDA has approved a new drug derived from a component of the cannabis sativa plant for the treatment of 2 rare forms of epilepsy.
Based on the results of 3 placebo-controlled studies, the FDA has approved a new drug derived from a component of the cannabis sativa plant for the treatment of 2 rare forms of epilepsy.
Based on the results of 3 placebo-controlled studies, the FDA has approved a new drug derived from a component of the cannabis sativa plant for the treatment of 2 rare forms of epilepsy.
